Community Publications

Key contributions made by BEAT-HIV CAB members present and past are acknowledged with their inclusion as named authors on the following publications.

Meanley S, Carter W, Short WB, Metzger DS, Onorato A, Montaner LJ, Dubé K. Provider awareness, attitudes, and willingness to support patient outreach efforts for HIV cure-directed research in Philadelphia, Pennsylvania. Open Forum Infect Dis. In press.
Dubé K, Villa TJ, Freshwater W, Mauk B, Rid A, Peluso MJ. Partner protections in HIV cure-related trials involving analytical treatment interruption: Updated toolkit to mitigate HIV transmission risk. J Virus Erad. 2024 Sep 11;10(3):100386.
Bilger A, Plenn E, Barg FK, Rendle KA, Carter WB, Lamour-Harrington A, Jones N, Peterson B, Sauceda JA, Tebas P, Mounzer K, Metzger D, Montaner LJ, Dubé K. Participant experiences in HIV cure-directed trial with an extended analytical treatment interruption in Philadelphia, United States. HIV Res Clin Pract. 2023 Oct 6;24(1):2267825.
Dubé K, Peterson B, Jones NL, Onorato A, Carter WB, Dannaway C, Johnson S, Hayes R, Hill M, Maddox R, Riley JL, Shull J, Metzger D, Montaner LJ. Community engagement group model in basic and biomedical research: lessons learned from the BEAT-HIV Delaney Collaboratory towards an HIV-1 cure. Res Involv Engagem. 2023 Jun 8;9(1):39.
Dubé K, Morton T, Fox L, Dee L, Palm D, Villa TJ, Freshwater W, Taylor J, Graham G, Carter WB, Sauceda JA, Peluso MJ, Rid A. A partner protection package for HIV cure-related trials involving analytical treatment interruptions. Lancet Infect Dis. 2023 Jun 6:S1473-3099(23)00267-0.
Dubé K, Villa TJ, Taylor J, Kaytes A, Moore DJ, Little SJ, Chaillon A, Smith DM, Gianella S. A Community-Driven Framework to Prioritize the Use of Donated Human Biological Materials in the Context of HIV Cure-Related Research at the End of Life. Pathog Immun. 2023 May 24;8(1):1-16.
Dubé K, Kanazawa J, Roebuck C, Johnson S, Carter WB, Dee L, Peterson B, Lynn KM, Lalley-Chareczko L, Hiserodt E, Kim S, Rosenbloom D, Evans BR, Anderson M, Hazuda DJ, Shipley L, Bateman K, Howell BJ, Mounzer K, Tebas P, Montaner LJ. “We are looking at the future right now”: Community acceptability of a home-based viral load test device in the context of HIV cure-related research with analytical treatment interruptions in the United States. HIV Research & Clinical Practice. 2022 December. 23(1): 120-135.
Dubé K, Agarwal H, Carter WB, Dee L, Taylor J, Roebuck C, Peterson B, Patel H, Ndukwe S, Lynn KM, Lalley-Chareczko L, Hiserodt E, Kim S, Rosenbloom D, Evans BR, Anderson M, Hazuda DJ, Bateman K, Howell BJ, Azzoni L, Mounzer K, Tebas P, Montaner LJ. Participant experiences using novel home-based blood collection device for viral load testing in the context of HIV cure trials with analytical treatment interruptions. HIV Research & Clinical Practice. 2022 Aug 2. 23(1):76-90.
Campbell DM, Dubé K, Cowlings PD, Dionicio P, Tam RM, Agarwal H, Stockman JK, Auerbach JD, Sauceda JA, Conroy AA, Johnson MO. “It comes altogether as one:” perceptions of analytical treatment interruptions and partner protections among racial, ethnic, sex and gender diverse HIV serodifferent couples in the United States. BMC Public Health. 2022 Jul 9;22(1):1317.
Dubé K, Eskaf S, Hastie E, Agarwal H, Henley L, Roebuck C, Carter WB, Dee L, Taylor J, Mapp D, Campbell DM, Villa TJ, Peterson B, Lynn KM, Lalley-Chareczko L, Hiserodt E, Kim S, Rosenbloom D, Evans BR, Anderson M, Hazuda DJ, Shipley L, Bateman K, Howell BJ, Mounzer K, Tebas P, Montaner LJ. Preliminary Acceptability of a Home-Based Peripheral Blood Collection Device for Viral Load Testing in the Context of Analytical Treatment Interruptions in HIV Cure Trials: Results from a Nationwide Survey in the United States. J Pers Med. 2022 Feb 7;12(2): 231.

Funding Acknowledgment

BEAT-HIV is funded by UM1 AI164570 and co-funded by NHLBI, NINDS, NIDDK, NIDA and the National Institute of Allergy and Infectious Diseases as well as The Robert I. Jacobs Fund of The Philadelphia Foundation.